LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: BMJ Publishing Group
Languages: English
Types: Article
Subjects: Primary Care
Identifiers:pmc:PMC100318
Objective To determine whether a three day burst of\ud a potent corticosteroid is more effective than a mild\ud preparation used for seven days in children with mild\ud or moderate atopic eczema.\ud Design Randomised, double blind, parallel group\ud study of 18 weeks' duration.\ud Setting 13 general practices and a teaching hospital\ud in the Nottingham area.\ud Participants 174 children with mild or moderate\ud atopic eczema recruited from general practices and\ud 33 from a hospital outpatient clinic.\ud Interventions 0.1% betamethasone valerate applied\ud for three days followed by the base ointment for four\ud days versus 1% hydrocortisone applied for seven days.\ud Main outcome measures Primary outcomes were\ud total number of scratch­free days and number of\ud relapses. Secondary outcomes were median duration\ud of relapses, number of undisturbed nights, disease\ud severity (six area, six sign atopic dermatitis severity\ud scale), scores on two quality of life measures\ud (children's life quality index and dermatitis family\ud impact questionnaire), and number of patients in\ud whom treatment failed in each arm.\ud Results No differences were found between the two\ud groups. This was consistent for all outcomes. The\ud median number of scratch­free days was 118.0 for the\ud mild group and 117.5 for the potent group (difference\ud 0.5, 95% confidence interval - 2.0 to 4.0, P = 0.53).\ud The median number of relapses for both groups was\ud 1.0. Both groups showed clinically important\ud improvements in disease severity and quality of life\ud compared with baseline.\ud Conclusion A short burst of a potent topical\ud corticosteroid is just as effective as prolonged use of a\ud milder preparation for controlling mild or moderate\ud atopic eczema in children.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1 Emerson RM, Williams HC, Allen BR. Severity distribution of atopic dermatitis in the community and its relationship to secondary referral. Br J Dermatol 1998;139:73­6.
    • 2 Williams HC, Wuthrich B. The natural history of atopic dermatitis. In: Williams HC, ed. Atopic dermatitis. Cambridge: Cambridge University Press, 2000, 41­59.
    • 3 McHenry P, Williams HC, Bingham EA. Treatment of atopic eczema. BMJ 1995;310:843­7.
    • 4 Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000;142:931­6.
    • 5 Fisher G. Compliance problems in paediatric atopic eczema. Aust J Dermatol 1996;37:10­3S.
    • 6 Hoare C, Li Wan Po A, Williams HC. Systematic review of treatments for atopic eczema. Health Technol Assess 2000;4(37):25­8.
    • 7 Hepburn DJ, Aeling JL, Weston WL. A reappraisal of topical steroid potency. Pediatr Dermatol 1996;13:239­45.
    • 8 Hornstein O. Guidelines for topical treatment of atopic eczema. In: Ruzicka T, Ring J, Pryzbilla B, eds. Handbook of atopic eczema. Heidelberg: Springer­Verlag, 1991:350.
    • 9 Schachner LA. A 3­day rate of efficacy of a moderate potency topical steroid in the treatment of atopic dermatitis in infancy and childhood. Pediatr Dermatol 1996;13:513­4.
    • 10 British Medical Association, Royal Pharmaceutical Society of Great Britain. British national formulary. London: BMA, RPS, 2000:508­20. (No 40.)
    • 11 Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, et al. The UK working party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994;131:383­96.
    • 12 Emerson RM, Charman CR, Williams HC. The Nottingham eczema severity score: preliminary refinement of the Rajka and Langeland grading. Br J Dermatol 2000;142:288­97.
    • 13 Charman C, Williams H. Outcome measures of disease severity in atopic eczema. Arch Dermatol 2000;136:763­9.
    • 14 Berth­Jones J. Six area, six sign atopic dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol 1996;135(suppl 48):25­30.
    • 15 Emerson RM, Williams HC, Allen BR, Mehta R, Finlay AY. How much disability does atopic eczema cause compared with other health problems? Br J Dermatol 1997;137(suppl 50):19.
    • 16 Lawson V, Lewis­Jones MS, Finlay AY, Reid P, Owens RG. The family impact of childhood atopic dermatitis: the dermatitis family impact questionnaire. Br J Dermatol 1998;138:107­13.
    • 17 Personal Social Services Research Unit. In: Netton A, Dennett J, eds. Unit costs of health and social care. Canterbury: PSSRU, 2000:sections 6.1, 8.7.
    • 18 Tsukahara KTY, Moriwaki S, Fujimura T, Imokawa G. Dermal fluid translocation is an important determinant of the diurnal variation in human skin thickness. Br J Dermatol 2001;145:590­6.
    • 19 Serup JKJ, Fullerton A. High­frequency ultrasound examination of skin: introduction and guide. In: Serup JJ, Jemec GBE, eds. Handbook of non­invasive methods and the skin. London: CRC Press, 1995.
    • 20 Van Onselen J. Dermatology care: the next role for primary care nurses. Community Nurse 1998;Sept:28­30.
    • 21 Van der Meer JB, Glazenburg EJ, Mulder PGH, Eggink HK, Coenraads PJ. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Br J Dermatol 1999;140:1114­21.
    • 22 Sillevis S, Spuls P, Van Leent E, Vries H, Mulder P, Glazenburg E, et al. Randomized double blind comparison of continuous versus pulse topical treatment with clobetasone butyrate in 40 children with atopic dermatitis. In: International symposium on atopic dermatitis. Portland, OR: National Eczema Association for Science and Education, 2001.
    • 23 Glazenburg E, Graham­Brown R, Hanifin J, Berth­Jones J, van der Meer J. Intermittent dosing with topical fluticasone propionate delays the time to relapse in adults and children with chronic atopic dermatitis-two randomised controlled studies. J Invest Dermatol 2001;117:533.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article